Neuro-oncology Research Group, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Blood. 2011 Sep 29;118(13):3680-3. doi: 10.1182/blood-2011-03-344408. Epub 2011 Aug 10.
Diagnostic platforms providing biomarkers that are highly predictive for diagnosing, monitoring, and stratifying cancer patients are key instruments in the development of personalized medicine. We demonstrate that tumor cells transfer (mutant) RNA into blood platelets in vitro and in vivo, and show that blood platelets isolated from glioma and prostate cancer patients contain the cancer-associated RNA biomarkers EGFRvIII and PCA3, respectively. In addition, gene-expression profiling revealed a distinct RNA signature in platelets from glioma patients compared with normal control subjects. Because platelets are easily accessible and isolated, they may form an attractive platform for the companion diagnostics of cancer.
诊断平台提供的生物标志物对癌症患者的诊断、监测和分层具有高度预测性,是个性化医疗发展的关键工具。我们证明肿瘤细胞在体外和体内将(突变)RNA转移到血小板中,并表明分离自胶质母细胞瘤和前列腺癌患者的血小板分别含有癌症相关的 RNA 生物标志物 EGFRvIII 和 PCA3。此外,基因表达谱分析显示,与正常对照相比,来自胶质母细胞瘤患者的血小板存在明显不同的 RNA 特征。由于血小板易于获取和分离,因此它们可能成为癌症伴随诊断的有吸引力的平台。